Paper14612901
The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer.
Bromwich EJ and 6 others. Br J Cancer, 2003. Cited by 136 papers, by iCite.
Cite this record
ConductScience Library. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Papers, record 14612901. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/14612901
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Renal Cell | Major topic |
| Kidney Neoplasms | Major topic |
| Neoplasm Staging | Major topic |
| T-Lymphocytes | Major topic |
| Aged | |
| Cohort Studies | |
| Female | |
| Humans | |
| Immunohistochemistry | |
| Male | |
| Middle Aged | |
| Survival Analysis | |
| Treatment Outcome |
Source PubMed
References6
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12681265 | Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. | Lancet Oncol | 2003 | https://conductscience.org/library/papers/12681265 | PubMed |
| 2 | 9307205 | TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). | Cancer | 1997 | https://conductscience.org/library/papers/9307205 | PubMed |
| 3 | 9721846 | CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. | Cancer Res | 1998 | https://conductscience.org/library/papers/9721846 | PubMed |
| 4 | 11431351 | Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. | Cancer Res | 2001 | https://conductscience.org/library/papers/11431351 | PubMed |
| 5 | 1495948 | The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma. | Mod Pathol | 1992 | https://conductscience.org/library/papers/1495948 | PubMed |
| 6 | 11229684 | Inflammation and cancer: back to Virchow? | Lancet | 2001 | https://conductscience.org/library/papers/11229684 | PubMed |
Cited by84
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 136 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41006825 | The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers. | Nat Rev Urol | 2026 | https://conductscience.org/library/papers/41006825 | PubMed |
| 40016487 | Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial. | Nat Cancer | 2025 | https://conductscience.org/library/papers/40016487 | PubMed |
| 39931080 | Uridine-cytidine kinase 2 is correlated with immune, DNA damage repair and promotion of cancer stemness in pan-cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/39931080 | PubMed |
| 39738081 | The expression of CCL17 and potential prognostic value on tumor immunity in thyroid carcinoma based on bioinformatics analysis. | Sci Rep | 2024 | https://conductscience.org/library/papers/39738081 | PubMed |
| 39351351 | Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer. | Front Oncol | 2024 | https://conductscience.org/library/papers/39351351 | PubMed |
| 39264227 | Prognostic value of tumor-infiltrating lymphocytes and PD-L1 expression in esophageal squamous cell carcinoma. | Cancer Med | 2024 | https://conductscience.org/library/papers/39264227 | PubMed |
| 38827239 | The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. | Biomark Insights | 2024 | https://conductscience.org/library/papers/38827239 | PubMed |
| 38277230 | Identification of molecular characteristics of FUT8 and alteration of core fucosylation in kidney renal clear cell cancer. | Aging (Albany NY) | 2024 | https://conductscience.org/library/papers/38277230 | PubMed |
| 37496661 | A reactive oxygen species-related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma. | Front Oncol | 2023 | https://conductscience.org/library/papers/37496661 | PubMed |
| 37362244 | Tumor subtypes and signature model construction based on chromatin regulators for better prediction of prognosis in uveal melanoma. | Pathol Oncol Res | 2023 | https://conductscience.org/library/papers/37362244 | PubMed |
| 37277702 | The predictive value of CD4, CD8, and C-reactive protein in the prognosis of schistosomal and non-schistosomal colorectal cancer. | BMC Gastroenterol | 2023 | https://conductscience.org/library/papers/37277702 | PubMed |
| 36417422 | Bioinformatics analysis of immune-related prognostic genes and immunotherapy in renal clear cell carcinoma. | PLoS One | 2022 | https://conductscience.org/library/papers/36417422 | PubMed |
| 36389779 | Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? | Front Immunol | 2022 | https://conductscience.org/library/papers/36389779 | PubMed |
| 36253752 | CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule. | BMC Cancer | 2022 | https://conductscience.org/library/papers/36253752 | PubMed |
| 36077742 | Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG). | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36077742 | PubMed |
| 35758895 | A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. | Cancer Discov | 2022 | https://conductscience.org/library/papers/35758895 | PubMed |
| 35485300 | Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway. | Bioengineered | 2022 | https://conductscience.org/library/papers/35485300 | PubMed |
| 35189004 | CENPF as an independent prognostic and metastasis biomarker corresponding to CD4+ memory T cells in cutaneous melanoma. | Cancer Sci | 2022 | https://conductscience.org/library/papers/35189004 | PubMed |
| 34831452 | From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. | Cells | 2021 | https://conductscience.org/library/papers/34831452 | PubMed |
| 33996558 | Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. | Front Oncol | 2021 | https://conductscience.org/library/papers/33996558 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| TENM1 | 10178 | PubTator's text mining | https://conductscience.org/library/genes/10178 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/14612901
GET https://conductscience.org/api/papers/v1/14612901/cited_by?page=2